News & Updates
Filter by Specialty:
No benefit to adding 5-ASAs to steroids in acute severe UC
The addition of 5-aminosalicylic acid (5-ASA) to standard corticosteroid treatment did not improve outcomes in patients hospitalized with acute severe ulcerative colitis (UC), according to a study presented at the Crohn’s and Colitis Congress 2022.
No benefit to adding 5-ASAs to steroids in acute severe UC
11 Feb 2022Which factor impels offering of postoperative chemotherapy in nonmuscle invasive bladder cancer?
A recent study has shown clear preferences by urologists when providing postoperative immediate chemotherapy in nonmuscle invasive bladder cancer (NMIBC). Factors beyond clinical variables, such as the structure of the recovery room, play a role in this decision-making process.
Which factor impels offering of postoperative chemotherapy in nonmuscle invasive bladder cancer?
11 Feb 2022Bivalent HPV vaccine substantially reduces cervical cancer, CIN3 rates
The risk of cervical cancer and grade 3 cervical intraepithelial neoplasia (CIN3) was substantially reduced among girls who were offered the bivalent human papillomavirus (HPV) vaccine, particularly those who were offered it at age 12–13 years, according to an observational study from England.
Bivalent HPV vaccine substantially reduces cervical cancer, CIN3 rates
10 Feb 2022Extensive influenza testing needed in pneumonia patients
Most patients with community-acquired pneumonia go untested for influenza even during flu season, which is unfortunate since a positive test result facilitates antiviral therapy, and early treatment leads to lower mortality, according to a study.
Extensive influenza testing needed in pneumonia patients
10 Feb 2022Casirivimab-imdevimab combo prevents progression from asymptomatic to symptomatic COVID-19
Treatment with the combination therapy of casirivimab and imdevimab prevents the risk of developing symptomatic COVID-19 among asymptomatic individuals with SARS-CoV-2 infection in a household close-contact setting, according to a recent study.